CureVac N.V.
CVAC · NASDAQ
11/24/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $494 | $1 | $1 | $14 |
| % Growth | 39,570.8% | 39.4% | -93.8% | – |
| Cost of Goods Sold | -$22 | $2 | $1 | $1 |
| Gross Profit | $473 | -$1 | $0 | $13 |
| % Margin | 95.8% | -77.8% | 2% | 89.7% |
| R&D Expenses | -$50 | $35 | $38 | $44 |
| G&A Expenses | $0 | $21 | $16 | $17 |
| SG&A Expenses | -$17 | $23 | $17 | $19 |
| Sales & Mktg Exp. | -$2 | $1 | $1 | $1 |
| Other Operating Expenses | -$37 | $3 | -$0 | -$4 |
| Operating Expenses | -$33 | $61 | $55 | $57 |
| Operating Income | $368 | -$62 | -$55 | -$44 |
| % Margin | 74.6% | -4,959.5% | -6,128.4% | -302.4% |
| Other Income/Exp. Net | -$35 | $2 | $3 | $5 |
| Pre-Tax Income | $371 | -$60 | -$52 | -$39 |
| Tax Expense | -$33 | -$0 | $0 | -$6 |
| Net Income | $338 | -$60 | -$52 | -$33 |
| % Margin | 68.4% | -4,783.9% | -5,832.5% | -226.4% |
| EPS | 1.5 | -0.26 | -0.23 | -0.15 |
| % Growth | 676.9% | -13% | -53.3% | – |
| EPS Diluted | 1.5 | -0.26 | -0.23 | -0.15 |
| Weighted Avg Shares Out | 225 | 225 | 225 | 224 |
| Weighted Avg Shares Out Dil | 225 | 225 | 225 | 225 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4 | $2 | $3 | $4 |
| Interest Expense | $7 | $1 | $0 | -$1 |
| Depreciation & Amortization | $0 | $4 | $5 | $4 |
| EBITDA | $0 | -$55 | -$47 | -$35 |
| % Margin | 0% | -4,417.1% | -5,234.6% | -241.2% |